SIT-047 / Sitryx, Eli Lilly - LARVOL DELTA

Sitryx nominates SIT-047, a novel, oral MTHFD2 inhibitor, for clinical development in psoriatic arthritis (GlobeNewswire) - "Sitryx Therapeutics...today announces the nomination of SIT-047, a novel, oral MTHFD2 inhibitor, as the latest development candidate from its proprietary pipeline to progress to regulatory non-clinical studies to support a Clinical Trial Authorisation (CTA)....SIT-047 has demonstrated strong efficacy in preclinical models and represents a promising precision immunometabolic approach to immune modulation."

Pipeline update • Preclinical • Psoriatic Arthritis